+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study



De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study



American Journal of Hematology 89(11): E193



It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 429 with ≥30% blasts (AML30), as well as 151 patients with 10-19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4-year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P = 0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P < 0.0001), hemoglobin (P = 0.005), UKMRC karyotype risk group (P = 0.002), normal BM karyotype (P = 0.004), treatment with induction therapy (P < 0.0001), and stem cell transplant (P < 0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052451291

Download citation: RISBibTeXText

PMID: 25042343

DOI: 10.1002/ajh.23808


Related references

AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 94(2): 832-833, 1999

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterranean Journal of Hematology and Infectious Diseases 5(1): E2013032, 2013

The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study. American Journal of Hematology 86(5): 437-439, 2011

The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts. Zhonghua Xue Ye Xue Za Zhi 38(10): 876-882, 2017

Diphtheria toxin/interleukin-3 fusion protein is toxic to blasts from patients with acute phase chronic myeloid leukemia and acute myeloid leukemia. Proceedings of the American Association for Cancer Research Annual Meeting (41): 285, 2000

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 93(8): 1263-1265, 2008

Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts. American Journal of Hematology 91(4): E273, 2016

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia. Leukemia and Lymphoma 58(11): 2717-2719, 2017

De novo acute myeloid leukemia with monocytoid blasts and erythrophagocytosis. Clinical Case Reports 2(6): 333-335, 2014

Phase II study of high dose lenalidomide as initial treatment for older acute myeloid leukemia patients: Early results show a significant reduction of bone marrow blasts after 14 days of therapy.. 2007

Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma. Blood 130(2): 231, 2017

Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?. Clinical Lymphoma Myeloma and Leukemia 11(4): 342-349, 2011

Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts. Leukemia 11(4): 561-571, 1997

Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genetics 205(4): 190-191, 2012

Activities of deoxycytidine deaminase and polymerase alpha in acute myeloid leukemia blasts and normal hematopoietic bone marrow cells. Experimental Hematology 24(9): 1121, 1996